Standard Practice for Real-time Release Testing of Pharmaceutical Water for the Total Organic Carbon Attribute

SIGNIFICANCE AND USE
5.1 Pharmaceutical water is the most common component or ingredient used in pharmaceutical and biopharmaceutical manufacturing. Acceptable purity of the water is important to the quality of the final pharmaceutical product. TOC concentration is a key indicator and attribute of the purity of this water and also an important monitor of the overall performance of the water purification system. TOC analysis is the measurement of all the covalently bound carbon present in the water, not including carbon in the form of carbon dioxide (CO2), bicarbonate icon (HCO3 –), or carbonate ion (CO3 2–), and is reported as the mass of organic carbon per volume.  
5.2 Application of this practice provides pertinent information to make informed decisions on the release of water meeting pharmaceutical TOC concentration specifications.
SCOPE
1.1 This practice establishes an approach to the real-time release testing (RTRT) of pharmaceutical water based on the total organic carbon (TOC) attribute using on-line total organic carbon (OLTOC) instrumentation that is in agreement with current regulatory thinking.  
1.2 This practice is harmonized with or supports the concepts of relevant ASTM International Committee E55 on Manufacture of Pharmaceutical Products standards, ICH Harmonized Tripartite Guidelines, the U.S. FDA PAT Guidance, and U.S. FDA Pharmaceutical cGMPs.  
1.3 This practice does not provide general guidance information for pharmaceutical procedures that are considered standard practice in the pharmaceutical industry. This practice provides specific guidance for non-standardized procedures.  
1.4 This practice does not address the user’s various internal procedures for risk, change, or quality management systems. The overall project effort associated with this practice shall be proportional to the overall risk of failing the pharmaceutical water’s TOC concentration specification.  
1.5 This practice does not purport to establish how to comply with pharmacopeias. The RTRT methodology selected must assure compliance with the user’s current required pharmacopeias. However, compliance with pharmacopeia TOC methods is not necessarily sufficient to meet current regulatory expectations for RTRT.  
1.6 This practice does not purport to substitute for or replace compendial bioburden testing requirements. It is strictly applicable to the TOC attribute of water quality.  
1.7 This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate safety and health practices and determine the applicability of regulatory limitations prior to use.

General Information

Status
Published
Publication Date
31-Oct-2016
Current Stage
Ref Project

Relations

Buy Standard

Standard
ASTM E2656-16 - Standard Practice for Real-time Release Testing of Pharmaceutical Water for the Total Organic Carbon Attribute
English language
8 pages
sale 15% off
Preview
sale 15% off
Preview
Standard
REDLINE ASTM E2656-16 - Standard Practice for Real-time Release Testing of Pharmaceutical Water for the Total Organic Carbon Attribute
English language
8 pages
sale 15% off
Preview
sale 15% off
Preview

Standards Content (Sample)

This international standard was developed in accordance with internationally recognized principles on standardization established in the Decision on Principles for the
Development of International Standards, Guides and Recommendations issued by the World Trade Organization Technical Barriers to Trade (TBT) Committee.
Designation: E2656 − 16
Standard Practice for
Real-time Release Testing of Pharmaceutical Water for the
1
Total Organic Carbon Attribute
This standard is issued under the fixed designation E2656; the number immediately following the designation indicates the year of
original adoption or, in the case of revision, the year of last revision. A number in parentheses indicates the year of last reapproval. A
superscript epsilon (´) indicates an editorial change since the last revision or reapproval.
1. Scope 2. Referenced Documents
2
1.1 This practice establishes an approach to the real-time 2.1 ASTM Standards:
release testing (RTRT) of pharmaceutical water based on the E2281 Practice for Process Capability and Performance
total organic carbon (TOC) attribute using on-line total organic Measurement
carbon (OLTOC) instrumentation that is in agreement with E2363 Terminology Relating to Manufacturing of Pharma-
current regulatory thinking. ceutical and Biopharmaceutical Products in the Pharma-
ceutical and Biopharmaceutical Industry
1.2 This practice is harmonized with or supports the con-
E2500 Guide for Specification, Design, and Verification of
cepts of relevant ASTM International Committee E55 on
Pharmaceutical and Biopharmaceutical Manufacturing
Manufacture of Pharmaceutical Products standards, ICH Har-
Systems and Equipment
monized Tripartite Guidelines, the U.S. FDA PAT Guidance,
E2537 Guide for Application of Continuous Process Verifi-
and U.S. FDA Pharmaceutical cGMPs.
cation to Pharmaceutical and Biopharmaceutical Manu-
1.3 This practice does not provide general guidance infor-
facturing
mation for pharmaceutical procedures that are considered
D4839 Test Method for Total Carbon and Organic Carbon in
standard practice in the pharmaceutical industry. This practice
Water by Ultraviolet, or Persulfate Oxidation, or Both, and
provides specific guidance for non-standardized procedures.
Infrared Detection
1.4 This practice does not address the user’s various internal D5173 Guide for On-Line Monitoring of Total Organic
Carbon in Water by Oxidation and Detection of Resulting
procedures for risk, change, or quality management systems.
The overall project effort associated with this practice shall be Carbon Dioxide
D5904 Test Method for Total Carbon, Inorganic Carbon, and
proportional to the overall risk of failing the pharmaceutical
Organic Carbon in Water by Ultraviolet, Persulfate
water’s TOC concentration specification.
Oxidation, and Membrane Conductivity Detection
1.5 This practice does not purport to establish how to
D5997 Test Method for On-Line Monitoring of Total
comply with pharmacopeias. The RTRT methodology selected
Carbon, Inorganic Carbon in Water by Ultraviolet, Persul-
must assure compliance with the user’s current required
fate Oxidation, and Membrane Conductivity Detection
pharmacopeias. However, compliance with pharmacopeia TOC
D6317 Test Method for Low Level Determination of Total
methods is not necessarily sufficient to meet current regulatory
Carbon, Inorganic Carbon and Organic Carbon in Water
expectations for RTRT.
by Ultraviolet, Persulfate Oxidation, and Membrane Con-
1.6 This practice does not purport to substitute for or replace
ductivity Detection
compendial bioburden testing requirements. It is strictly appli-
2.2 Pharmacopoeia Documents:
cable to the TOC attribute of water quality.
ICH Q2 (R1) Validation of Analytical Procedures: Text and
3
1.7 This standard does not purport to address all of the
Methodology
safety concerns, if any, associated with its use. It is the
ICH Q7 Good Manufacturing Practice Guide for Active
3
responsibility of the user of this standard to establish appro-
Pharmaceutical Ingredients
priate safety and health practices and determine the applica-
bility of regulatory limitations prior to use.
2
For referenced ASTM standards, visit the ASTM website, www.astm.org, or
contact ASTM Customer Service at service@astm.org. For Annual Book of ASTM
1
This practice is under the jurisdiction of ASTM Committee E55 on Manufac- Standards volume information, refer to the standard’s Document Summary page on
ture of Pharmaceutical and Biopharmaceutical Products and is the direct responsi- the ASTM website.
3
bility of Subcommittee E55.12 on Process Applications. Available from International Conference on Harmonisation of Technical
Current edition approved Nov. 1, 2016. Published November 2016. Originally Requirements for Registration of Pharmaceuticals for Human Use (ICH), ICH
approved in 2010. Last previous edition approved in 2010 as E2656 – 10. DOI: Secretariat, c/o IFPMA, 15 ch. Louis-Dunant, P.O. Box 195, 1211 Geneva 20,
10.1520/E2656-16. Switzerland, http://www.ich.
...

This document is not an ASTM standard and is intended only to provide the user of an ASTM standard an indication of what changes have been made to the previous version. Because
it may not be technically possible to adequately depict all changes accurately, ASTM recommends that users consult prior editions as appropriate. In all cases only the current version
of the standard as published by ASTM is to be considered the official document.
Designation: E2656 − 10 E2656 − 16
Standard Practice for
Real-time Release Testing of Pharmaceutical Water for the
1
Total Organic Carbon Attribute
This standard is issued under the fixed designation E2656; the number immediately following the designation indicates the year of
original adoption or, in the case of revision, the year of last revision. A number in parentheses indicates the year of last reapproval. A
superscript epsilon (´) indicates an editorial change since the last revision or reapproval.
1. Scope
1.1 This practice establishes an approach to the real-time release testing (RTRT) of pharmaceutical water based on the total
organic carbon (TOC) attribute using on-line total organic carbon (OLTOC) instrumentation that is in agreement with current
regulatory thinking.
1.2 This practice is harmonized with or supports the concepts of relevant ASTM International Committee E55 on Manufacture
of Pharmaceutical Products standards, ICH Harmonized Tripartite Guidelines, the USU.S. FDA PAT Guidance, and USU.S. FDA
Pharmaceutical cGMPs.
1.3 This practice does not provide general guidance information for pharmaceutical procedures that are considered standard
practice in the pharmaceutical industry. This practice provides specific guidance for non-standardized procedures.
1.4 This practice does not address the user’s various internal procedures for risk, change, or quality management systems. The
overall project effort associated with this practice shall be proportional to the overall risk of failing the pharmaceutical water’s TOC
concentration specification.
1.5 This practice does not purport to establish how to comply with pharmacopeias. The RTRT methodology selected must assure
compliance with the user’s current required pharmacopeias. However, compliance with pharmacopeia TOC methods is not
necessarily sufficient to meet current regulatory expectations for RTRT.
1.6 This practice does not purport to substitute for or replace compendial bioburden testing requirements. It is strictly applicable
to the TOC attribute of water quality.
1.7 This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility
of the user of this standard to establish appropriate safety and health practices and determine the applicability of regulatory
limitations prior to use.
2. Referenced Documents
2
2.1 ASTM Standards:
E2281 Practice for Process Capability and Performance Measurement
E2363 Terminology Relating to Process Analytical Technology in the Pharmaceutical Industry
E2500 Guide for Specification, Design, and Verification of Pharmaceutical and Biopharmaceutical Manufacturing Systems and
Equipment
E2537 Guide for Application of Continuous Quality Verification to Pharmaceutical and Biopharmaceutical Manufacturing
D4839 Test Method for Total Carbon and Organic Carbon in Water by Ultraviolet, or Persulfate Oxidation, or Both, and Infrared
Detection
D5173 Guide for On-Line Monitoring of Total Organic Carbon in Water by Oxidation and Detection of Resulting Carbon
Dioxide
D5904 Test Method for Total Carbon, Inorganic Carbon, and Organic Carbon in Water by Ultraviolet, Persulfate Oxidation, and
Membrane Conductivity Detection
1
This practice is under the jurisdiction of ASTM Committee E55 on Manufacture of Pharmaceutical and Biopharmaceutical Products and is the direct responsibility of
Subcommittee E55.03 on General Pharmaceutical Standards.
Current edition approved Aug. 1, 2010Nov. 1, 2016. Published October 2010November 2016. Originally approved in 2010. Last previous edition approved in 2010 as
E2656 – 10. DOI: 10.1520/E2656-10.10.1520/E2656-16.
2
For referenced ASTM standards, visit the ASTM website, www.astm.org, or contact ASTM Customer Service at service@astm.org. For Annual Book of ASTM Standards
volume information, refer to the standard’s Document Summary page on the ASTM website.
Copyright © ASTM International, 100 Barr Harbor Drive, PO Box C700, West Conshohocken, PA 19428-2959. United States
1

---------------------- Page: 1 ----------------------
E2656 − 16
D5997 Test Method for On-Line Monitoring of Total Carbon, Inorganic Carbon in Water by Ultraviolet, Persulfate Oxidation,
and Membrane Conductivity Detection
D6317 Test Method for Low Level Determination of Total Carbon, Inorganic Carbon and Organic Carbon in Water by
Ultraviolet, Persulfate Oxidation, and Membrane Conductivity Detection
2.2 Pharmacopoeia Documents:
3
ICH Q2 (R1) Validation of Analytical Procedures: Text and Methodology
3
ICH Q7 Good Manufacturing Practice
...

Questions, Comments and Discussion

Ask us and Technical Secretary will try to provide an answer. You can facilitate discussion about the standard in here.